AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager

AstraZeneca is boosting its roster with the acquisition of TeneoTwo, which currently has a Phase 1 trial testing its newest treatment for blood cancer, in a deal valued up to 1.27 billion dollars.
The transaction, expected to close in the third quarter of this year, includes TNB-486, which is part of a class of therapeutic antibodies called T-cell engagers. These are emerging as promising treatments for solid tumors and hematologic malignancies. The drug is also being considered for diffuse large B-cell lymphoma and follicular lymphoma. Bringing TeneoTwo into the fold allows Astrazeneca to build on the success of Calquence and further strengthen its pipeline.